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Abstract  22 
Context: Previous studies suggested a possible increased risk of hypercalcaemia and reduced bone 23 
mineral density (BMD) in Williams’ Syndrome (WS). However, an extensive study regarding bone 24 
metabolism has never been performed.  25 
Objective: To investigate bone health in young adults with WS.  26 
Design: Cross-sectional study.  27 
Settings: Endocrinology and Metabolic Diseases and Medical Genetic Units.  28 
Patients: 29 WS young adults and 29 age- and sex-matched controls.  29 
Main Outcome Measures: In all subjects calcium, phosphorus, bone alkaline-phosphatase (bALP), 30 
parathyroid hormone (PTH), 25-hydroxyvitamin D (25OHVitD), osteocalcin (OC), 31 
carboxyterminal-cross-linking-telopeptide of type I collagen (CTX), 24-hour urinary calcium and 32 
phosphorus, femoral-neck (FN) and lumbar-spine (LS) BMD and vertebral fractures (VFx) were 33 
assessed. In 19 patients serum fibroblast-growth-factor-23 (FGF23) levels were measured. 34 
Results: WS patients showed lower phosphorus (3.1±0.7 vs 3.8±0.5 mg/dL, p=0.0001) and 35 
TmP/GFR (0.81±0.32 vs 1.06±0.25 mmol/L, p=0.001), and an increased prevalence (p=0.005) of 36 
hypophosphoremia (34.5 vs 3.4%) and reduced TmP/GFR (37.9 vs 3.4%). Moreover, bALP 37 
(26.3±8.5 U/L vs 35.0±8.0 U/L), PTH (24.5±12.6 vs 33.7±10.8 pg/mL), OC (19.4±5.3 vs 24.5±8.7 38 
ng/mL) and FN-BMD (-0.51±0.32 vs 0.36±0.32) were significantly lower (p<0.05), while CTX 39 
significantly higher (401.2±169.3 vs 322.3±122.4 pg/mL, p<0.05). Serum and urinary calcium and 40 
25OHVitD levels, LS-BMD and VFx prevalence were comparable. No cases of  hypercalcemia and 41 
suppressed FGF23 were documented. Patients with low versus normal phosphorus and low versus 42 
normal TmP/GFR showed comparable FGF23 levels. FGF23 did not correlate with phosphorus and 43 
TmP/GFR values.  44 
Conclusions: Adult WS patients have reduced TmP/GFR, inappropriately normal FGF23 levels 45 
and an uncoupled bone turnover with low femoral BMD.   46 
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Introduction  47 
Williams’ Syndrome (WS; OMIM #194050) is a rare genetic disorder caused by a 48 
hemizygous microdeletion on chromosome 7q11.23 with a prevalence ranging from 1/7500 to 49 
1/20000 live births [1-3]. The clinical phenotype is widely heterogeneous and is mainly 50 
characterised by unique facial dysmorphisms and personality, mild intellectual disability, growth 51 
retardation, impaired glucose metabolism, thyroid dysfunction and cardiovascular abnormalities [4, 52 
5]. In the past some studies found an increased risk of hypercalcaemia in WS patients. In particular, 53 
mild hypercalcaemia (serum calcium <11.5 mg/dl [2.88 mmol/L]) has been reported in 5 to 50% of 54 
WS patients [6-9], and some cases of severe hypercalcemia have been described in childhood [10]. 55 
The causal factor has not been clarified and various mechanisms, including a pathological 56 
metabolism of vitamin D or calcitonin, have been hypothesized [11, 12]. In addition, a previous not-57 
controlled study suggested that in WS a reduced bone mineral density (BMD) could be present [13], 58 
but data regarding calcium-phosphorous metabolism, bone turnover and the presence of 59 
asymptomatic vertebral fractures (VFx) in WS patients are completely lacking.  60 
Therefore, the aim of our study was to assess bone involvement in a population of young 61 
adults with WS compared with a control group by evaluating calcium-phosphorus metabolism, bone 62 
turnover indexes, the BMD and the prevalence of morphometric VFx.  63 
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Subjects and Methods  64 
Subjects  65 
From February to June 2016, 33 WS patients referred to the Medical Genetic Unit of our 66 
hospital were evaluated for the enrolment in the study. The diagnosis of WS was made clinically 67 
and confirmed in all cases by the typical ELN gene hemizygosity shown by FISH. None of the 68 
patients’ parents had the clinical features of WS, thus suggesting that all cases were de novo 69 
presentations. The exclusion criteria were the following: past or current history of diseases known 70 
to affect bone tissue (i.e., thyrotoxicosis, bowel diseases, chronic hepatic or renal diseases, 71 
alcoholism, rheumatologic or hematologic diseases, hypogonadism in males and postmenopausal 72 
status in females) and intake of diuretics or drugs influencing bone metabolism. Eventually, 29 WS 73 
young patients (13 females and 16 males, mean age 28.8±5.5 years) were included in the study. 74 
During the same period of time, 29 subjects matched for age and sex were consecutively enrolled as 75 
controls on the basis of the above-mentioned exclusion criteria from our outpatient clinics for 76 
Endocrine Diseases where they were referred for unrelated diseases (multinodular goiter with 77 
normal thyroid function without others pathological conditions).  78 
In all patients and controls, besides medical reports, clinical history and general chemistry 79 
profile, serum calcium, phosphorus, albumin, bone alkaline phosphatase (bALP), parathyroid 80 
hormone (PTH), 25-hydroxyvitamin D (25OHVitD), osteocalcin (OC) and serum carboxyterminal 81 
cross-linking telopeptide of type I collagen levels (CTX), urinary calcium and phosphorus in 3 and 82 
24 hours urine collection were measured. In 19 patients, we also evaluated serum fibroblast growth 83 
factor 23 (FGF23) levels on samples stored in a -20° C freezer until the time of testing. In all 84 
subjects the BMD at femoral neck (FN) and lumbar spine (LS) and VFx were assessed.  85 
 86 
Methods  87 
Weight and height were measured by standard procedures; body mass index (BMI) was 88 
calculated according to the formula weight (kg)/[height (m)]2 [14].  89 
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Serum and urinary samples were collected between 8 a.m. and 9 a.m. after 8 hours fasting. 90 
All samples were analysed in the same laboratory. Serum and urinary calcium and phosphorus, 91 
albumin and bALP were measured by standard techniques (reference intervals: serum calcium 8.4–92 
10.2 mg/dL [2.1–2.6 mmol/L], serum phosphorus 2.7-4.5 mg/dl [0.87–1.45 mmol/L], bALP 15-60 93 
U/L). Total calcium was corrected for serum albumin (Caalb adj) according to the formula Caalb 94 
adj (milligrams per deciliter) = total calcium + [(4.4 - albumin in grams per deciliter) x 0.8] [15]. 95 
Measurement of ionized calcium was made using calcium ion-selective electrode direct 96 
potentiometry (reference interval 1.13-1.32 mmol/L). Hypercalciuria was defined as urinary 97 
calcium excretion of ≥4 mg/kg body weight/day in both sexes [16]. Serum intact PTH levels were 98 
measured by a two-step automated sandwich chemiluminescent immunoassay (CLIA; DiaSorin), 99 
with intra- and interassay coefficients of variation (CVs) <10 % (reference interval 6.5– 36.8 pg/mL 100 
[6.5–36.8 ng/L]). Serum 25(OH)VitD concentration was measured by radioimmunoassay (RIA; 101 
DiaSorin), with intra- and interassay CVs of 7.2% and <12%, respectively (reference interval 30–102 
120 ng/mL [75–300 nmol/L]). Serum OC (normal values, 5–65 ng/mL [µg/L]) was measured by the 103 
Invitrogen human Osteocalcin Enzyme Amplified Sensitivity Immunoassay (Life Technologies) 104 
and serum CTX (normal values, 140–1350 pg/mL [ng/L]) was determined by the Serum CrossLaps 105 
ELISA (Immunodiagnostic System Ltd) according to the manufacturer’s assay procedure. Serum 106 
intact FGF23 was analysed by a two-site enzyme-linked immunosorbent assay (ELISA; Kainos 107 
Laboratories inc, Tokyo, Japan) with a reference interval of 10–50 pg/ml [1.33-6.65 pmol/L] [17]. 108 
The ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR), 109 
normal values 2.5-4.2 mg/dl [0.80-1.35 mmol/L], was determined using the Walton and Bijvoet 110 
nomogram [18]. 111 
Bone mineral density (BMD) was measured by dual-energy X-ray Absorptiometry (DXA; 112 
Hologic Discovery QDR series, Waltham, MA, USA) at LS (in vivo precision 1.0%) and FN (in 113 
vivo precision 1.8 %). Individual BMD values were expressed as SD units (Z-scores). Fractured 114 
vertebrae were excluded from BMD measurement. 115 
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Conventional spinal radiographs in the lateral (T4 to L4) and anteroposterior projections 116 
were obtained in all patients by a standardized technique. Two physicians, blinded to the BMD and 117 
biochemical data, independently reviewed the radiographs. The questionable cases were discussed 118 
to reach an agreed diagnosis. VFx were diagnosed on visual inspection using the semi-quantitative 119 
visual assessment described by Genant et al., defined as a reduction of >20% in anterior, middle, or 120 
posterior vertebral height [19].  121 
 122 
Statistical analysis  123 
Statistical analysis was performed by SPSS version 21.0 (SPSS Inc, Chicago, IL). The 124 
results are expressed as means±standard deviation (SD) or medians±standard error (SE) in the case 125 
of non-Gaussian distribution. The normality of distribution was tested by the Kolmogorov-Smirnov 126 
test. The comparison of continuous variables was performed using the Student t test or Mann-127 
Whitney U test as appropriate. Categorical variables were compared by the χ2 test or Fisher exact 128 
test as appropriate. The comparison of the continuous variables among patients and controls, among 129 
patients with low and normal phosphorus and TmP/GFR values and among patients with high and 130 
normal FGF23 values was performed by one-way ANOVA. Logistic regression analysis was used 131 
to assess in patients the possible independent associations between the presence of low phosphorus 132 
and low TmP/GFR values (dependent variables) with age, BMI, sex, serum calcium, 25OHVitD, 133 
bALP, PTH, CTX, OC, FGF23 levels, urinary calcium levels, BMD and VFx (independent 134 
variables).  135 
P values ≤0.05 were considered significant.  136 
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Results 137 
The comparison of the basal clinical and biochemical characteristics between WS patients 138 
and controls is reported in Table 1. Age, sex and BMI were comparable between patients and 139 
controls. As expected for the disease, the height of the patients was significantly lower compared to 140 
controls. Considering endocrine comorbidities associated to WS, 4 out 29 (14%) patients had 141 
diabetes mellitus type 2 (1 patient on metformin therapy, 500 mg tid, and 3 patients on diet therapy) 142 
and 5 out 29 (17%) patients had primary hypothyroidism on replacement therapy with 143 
levothyroxine. Both diabetic and hypothyroid patients had a good control of the diseases (glycated 144 
hemoglobin < 53 mmol/mol, TSH values between 0.9 and 4.0 µIU/ml). Moreover 12 out 29 (41%) 145 
WS patients had one or more cardiovascular abnormalities (5 patients with supravalvular aortic 146 
stenosis, 1 patients with supravalvular pulmonary stenosis, 1 patient with peripheral pulmonary 147 
stenosis, 1 patient with aortic narrowing,  6 patients with mitral valve prolapse, 1 patient with aortic 148 
regurgitation and 2 patients with ventricular or atrial septal defects) and 19/29 (65%) were 149 
hypertensive. The fracture history was collected in all patients: no peripheral low trauma fractures 150 
were reported and, on the other side, no patients told of any accident or traumatic fall.  151 
All patients and controls had normal renal function. No differences were found in serum 152 
calcium levels between patients and controls, even if the formers showed slightly higher serum 153 
calcium levels than the letters. In particular, no patient was hypercalcemic at basal evaluation. The 154 
ionized calcium levels were significantly higher in patients than in controls albeit always in the 155 
normal range (p=0.017) (Figure 1). In particular, female WS patients tended to have higher blood 156 
calcium values than males (p=0.06).  157 
No difference was found in 24h urinary calcium levels between patients and controls but 158 
interestingly, female WS patients had an increased 24h urinary calcium excretion than males 159 
(p=0.005). This difference was absent in controls. 5 (17%) WS patients had hypercalciuria and, of 160 
note, 4 out 5 patients with hypercalciuria were female.   161 
Compared with controls, WS patients showed significantly lower serum phosphorus levels, 162 
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an increased prevalence of hypophosphatemia (serum phosphorus <2.7 mg/dL [<0.87 mmol/L]) 163 
(p=0.005), a significantly lower TmP/GFR and increased prevalence of reduced TmP/GFR (<2.5 164 
mg/dl [<0.80 mmol/L]) (p=0.005). None of the 10 patients with low phosphorus levels was 165 
symptomatic for hypophosphatemia and no differences were seen in phosphorus serum levels 166 
between male and female WS patients. The bALP, PTH and OC levels were significantly lower, 167 
while the CTX levels were significantly higher in patients than in controls. No differences were 168 
found in 25OHVitD levels and in the prevalence of low 25OHVitD levels (i.e., serum vitamin D 169 
<30 ng/mL [75 nmol/L]) between the two groups. Compared with controls, WS patients showed a 170 
reduced FN-BMD, while no differences were found in LS-BMD and in the prevalence of VFx 171 
between the two groups.  172 
FGF23 was elevated (>50 pg/ml [6.65 pmol/L]) in 6 out 19 (31.5%) tested WS patients. All 173 
biochemical and bone metabolism parameters and, in particular, phosphorus levels were 174 
comparable between WS patients with normal or elevated FGF23 levels. No patients had 175 
suppressed FGF23 values. 176 
The comparison of the basal clinical and biochemical characteristics between WS patients 177 
with low and normal TmP/GFR is reported in Table 2. Age, sex, BMI, serum and 24h urinary 178 
calcium levels, PTH, 25OHVitD, bone turnover markers, FGF23 levels, BMD and prevalence of 179 
VFx were comparable between patients with low and normal TmP/GFR. 180 
No correlation was found between FGF23 and phosphorus levels (r= -0.07, p=0.79) and 181 
between FGF23 and TmP/GFR values (r= -0.04, p=0.88). A negative correlation was found 182 
between FGF23 and CTX levels (r= -0.56 p=0.01). 183 
 184 
Discussion  185 
In this study we evaluated the bone involvement in a group of young adults with WS 186 
compared to an age and sex matched control group by assessing the calcium-phosphorus 187 
metabolism, the bone turnover indexes, the BMD and the prevalence of morphometric VFx. 188 
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Our data show that, at least in adulthood, hypercalcemia is a rare event in WS and that an 189 
hypophosphatemic disorder with a reduced TmP/GFR together with an inappropriately normal 190 
production of FGF23, an uncoupled bone turnover and a low bone mass at FN is a feature of this 191 
syndrome.  192 
The available studies reported hypercalcemia in 5% to 50% of WS patients, with a greater 193 
frequency of episodes in childhood and progressive reduction in adulthood [6-9], even if when 194 
paediatric reference intervals were applied, the occurrence of hypercalcemia in childhood dropped 195 
significantly [9]. The prevalence of hypercalcemia exclusively in adult WS patients was evaluated 196 
only in one study [13]. In this work, 1 out 20 (5%) patients showed moderately high levels of 197 
calcium (10.6 mg/dl [2.65 mmol/L]) together with an inappropriately normal PTH levels [13], thus 198 
possibly related to the presence of a primary hyperparathyroidism associated to WS.  In our study, 199 
no patient was hypercalcaemic, although ionized calcium values were significantly higher in 200 
patients than controls. Similarly in a recent study, Stagi et al., reported significantly higher ionised 201 
and total calcium levels in WS patients compared with age and sex-matched controls [20].   202 
The noteworthy and novel result of our study is the finding in WS patients of significantly 203 
lower serum phosphorus levels with a higher prevalence of asymptomatic hypophosphatemia with a 204 
reduced TmP/GFR representative of a renal phosphate loss disorder.  Additionally, despite the low 205 
phosphorus values, none of our patients had suppressed FGF23 levels, suggesting an inappropriate 206 
secretion of this phosphatonin. In particular, FGF23 values were higher in 31.5% of patients and 207 
within the normal range in the remaining 68% of patients. Up to now, only one study showed in WS 208 
patients serum phosphate levels lower in respect with controls, but no information was available 209 
regarding the prevalence of hypophosphatemia, the TmP/GFR and FGF23 levels [20]. 210 
The possibility that this inappropriate production of FGF23 could be caused by an 211 
augmented osteocytes/osteoblasts sensitivity to serum phosphorus levels or to an impaired action or 212 
catabolism of FGF23 remain to be evaluated. In fact, several factors are involved in the complex 213 
paracrine and endocrine activity of FGF23 in the kidney, including the protein Klotho [21-23] and 214 
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also the status of FGF23 O-glycosylation of threonine178 and FGF23 phosphorylation of serine180 215 
that significantly influence its expression and degradation [24]. Our data, however, did not show 216 
any correlation between FGF23, phosphorus and TmP/GFR values. This finding could be related to 217 
the low number of patients analysed, but it is conceivable that other phosphatonins, that were not 218 
assessed in our study (i.e. FGF7, MEPE and sFRP-4), could be involved. Unfortunately we do not 219 
have the possibility to dose FGF23 levels in our control group for a comparison. Beside this limit of 220 
the study, an analytical bias related to the assay used for FGF23 dosage cannot be excluded. In fact, 221 
it is well known that current ELISA kit for intact FGF23 showed little analytical agreement [25, 26] 222 
and that intact FGF23 appears to have greater intra-individual variation compared with his C-223 
terminal fragment [27]. Therefore, the lack of associations between FGF23 and phosphorus and/or 224 
TmP/GFR values could be linked to the type of assay used [25, 26].  225 
Overall, it must be considered that several aspects of FGF23 regulation remain incompletely 226 
understood. Indeed, besides the stimulatory effect of PTH (directly or via 1,25 hydroxy-227 
cholecalciferol) on FGF23 secretion, some data suggest that hypercalcemia also stimulates FGF23 228 
production, whereas hypocalcemia prevents normally expected FGF23 responses to phosphate 229 
overload [28, 29]. Therefore, it is not possible to exclude that in our sample of WS patients the 230 
tendency toward hypercalcemia may have contributed in maintaining the inappropriately normal 231 
FGF23. 232 
An additional important finding of the present study is that WS patients showed an 233 
uncoupled bone turnover (low bALP and OC and high CTX levels) associated with a reduction of 234 
cortical but not trabecular bone density. However, this is not accompanied by a statistically 235 
significant increase in the VFx prevalence, even though it must be observed that the 10% of our WS 236 
patients had a VFx, while no fractured subject was found in the control group. Previous data 237 
showed an impaired bone apposition in both adolescent and adults WS patients [13, 20], and an 238 
increased bone resorption in adults WS patients [20], together with a significantly impaired bone 239 
mineral status at quantitative bone ultrasonometry evaluation [20] and an increased prevalence of 240 
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osteopenia and osteoporosis [13]. In the present study we show for the first time that WS patients 241 
have a compromised cortical bone density at femur, while the trabecular spinal bone density seems 242 
to be preserved. Notwithstanding the normal BMD at spine, the WS patients may have an increased 243 
prevalence of VFx (10%), even though the present study is probably not enough powered to reach 244 
the statistical significance. The possible discrepancy between the possibly increased VFx 245 
prevalence and the normal spinal BMD could be explained by the presence of a reduced trabecular 246 
microarchitecture, which is not entirely captured by the DXA evaluation [30].  247 
The bone metabolism disorder in WS patients may be linked in part to the genetic 248 
predisposition itself. In fact, the haploinsufficiency of FDZ9, a gene involved in the early stages of 249 
osteoblastogenesis and bone formation [31], could explain the low levels of OC and bALP and the 250 
reduced BMD found in WS patients. Moreover, the alterations in phosphate homeostasis may affect 251 
the skeletal metabolism and in particular the osteoblast (OB) function, as demonstrated in OB 252 
cultures derived from Hyp mice (counterparts of X-linked hypophosphatemic rickets) [33] 253 
characterized by low bone mineralization [34]. It is also possible to hypothesize that the condition 254 
of hypophosphatemia and hyperphosphaturia activates bone resorption [34, 35]. This can explain 255 
the finding of elevated CTX and serum calcium levels and lower PTH levels in WS patients. The 256 
fact that CTX levels, though higher in WS patients than in controls, were still within the normal 257 
range in the former group, may be due to the fact that in WS bone resorption is only slightly 258 
increased. It should also observed that our patients were all eugonadal. Therefore, the normal range 259 
of CTX given by the manufacturer may be not entirely representative of the population enrolled in 260 
the present study 261 
Another possible causative factor of bone metabolism disorder in WS patients may be 262 
related to the reduced physical activity compared to controls as demonstrated in a previous study 263 
[20]. Neither joint mobility problems, nor physical limitations were reported by our patients but, 264 
unfortunately, a quantitative assessment of physical activity was not carried out.  265 
Finally, interestingly, we found a negative association between FGF23 and CTX levels. This 266 
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may be explained in part by the known inhibitory effect of FGF23 on PTH levels [36], but other 267 
factors (i.e. an excess in sclerostin production) not evaluated in our study may be involved.  268 
In conclusion, the present study shows that in WS there is a hypophosphatemic disorder 269 
with reduced TmP/GFR together with an inappropriate secretion of FGF23. Moreover, we found an 270 
uncoupled bone turnover associated with a significantly reduced cortical bone density at femur. 271 
Longitudinal studies on larger samples and with an adequate follow-up should be designed to 272 
identify the possible causative factors and the long-term complications of these findings. 273 
 274 
Compliance with Ethical Standards 275 
Conflict of Interest: The authors declare that they have no conflict of interest. 276 
Ethical approval: All procedures performed in studies involving human participants were in 277 
accordance with the ethical standards of the institutional and/or national research committee and 278 
with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 279 
Informed consent: Informed consent was obtained from all individual participants included in the 280 
study. 281 
 282 
References  283 
1. Morris CA. Introduction: Williams syndrome (2010) Am J Med Genet C Semin Med Genet. 284 
May 15;154C(2):203-8. 285 
2. Strømme P, Bjornstad P, Ramstad K (2002) Prevalence estimation of Williams syndrome. J 286 
Child Neurol.17:269–271. 287 
3. Schubert C (2009) The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci. 288 
Apr;66(7):1178-97. 289 
4. Pober BR (2010) Williams-Beuren syndrome. N Engl J Med Jan 21;362(3):239-52. Review.  290 
5. Masserini B, Bedeschi MF, Bianchi V, Scuvera G, Beck-Peccoz P, Lalatta F, Selicorni A, 291 
13 
 
Orsi E (2013) Prevalence of diabetes and pre-diabetes in a cohort of Italian young adults 292 
with Williams syndrome. Am J Med Genet A. Apr;161A(4):817-21. 293 
6. Sforzini C, Milani D, Fossali E, Barbato A, Grumieri G, Bianchetti MG, Selicorni A (2002) 294 
Renal tract ultrasonography and calcium homeostasis in Williams-Beuren syndrome. Pediatr 295 
Nephrol. Nov;17(11):899-902. 296 
7. Amenta S, Sofocleous C, Kolialexi A, Thomaidis L, Giouroukos S, Karavitakis E, Mavrou 297 
A, Kitsiou S, Kanavakis E, Fryssira H (2005) Clinical manifestations and molecular 298 
investigation of 50 patients with Williams syndrome in the Greek population. Pediatr Res. 299 
Jun;57(6):789-95. 300 
8. Pérez Jurado LA, Peoples R, Kaplan P, Hamel BC, Francke U (1996) Molecular definition 301 
of the chromosome 7 deletion in Williams syndrome and parent-of-origin effects on growth. 302 
Am J Hum Genet. Oct;59(4):781-92. 303 
9. Sindhar S, Lugo M, Levin MD, Danback JR, Brink BD, Yu E, Dietzen DJ, Clark AL, 304 
Purgert CA, Waxler JL, Elder RW, Pober BR, Kozel BA (2016) Hypercalcemia in Patients 305 
with Williams-Beuren Syndrome. J Pediatr. Nov; 178:254-260.e4. 306 
10. Cagle AP, Waguespack SG, Buckingham BA, Shankar RR, Dimeglio LA. Severe infantile 307 
hypercalcemia associated with Williams syndrome successfully treated with intravenously 308 
administered pamidronate. Pediatrics (2004) Oct;114(4):1091-5. 309 
11. Garabédian M, Jacqz E, Guillozo H, Grimberg R, Guillot M, Gagnadoux MF, Broyer M, 310 
Lenoir G, Balsan  (1985)  Elevated plasma 1,25-dihydroxyvitamin D concentrations in 311 
infants with hypercalcemia and an elfin facies N Engl J Med. Apr 11;312(15):948-52. 312 
12. Culler FL, Jones KL, Deftos LJ (1985) Imparied calcitonin secretion in patients with 313 
Williams syndrome. J Pediatr Nov;107(5):720-3. 314 
13. Cherniske EM, Carpenter TO, Klaiman C, Young E, Bregman J, Insogna K, Schultz RT, 315 
Pober BR (2004) Multisystem study of 20 older adults with Williams syndrome. Am J Med 316 
Genet A. 131:255–64. 317 
14 
 
14. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness (1985). Int J 318 
Obes.;9(2):147-53. 319 
15. UpToDate calculator. In Calcium Correction in Hypoalbuminemia, version 18.2. Waltham, 320 
MA: Wolters Kluwer-Health (available:www.uptodate.com), 2010. 321 
16. Hodgkinson A, Pyrah LN (1958) The urinary excretion of calcium and inorganic phosphate 322 
in 344 patients with calcium stone of renal origin. Br J Surg. Jul;46(195):10-8. 323 
17. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, 324 
Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically 325 
active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin 326 
Endocrinol Metab Nov;87(11):4957-60. 327 
18. Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate 328 
concentration. Lancet Aug 16;2(7929):309-10 329 
19. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a 330 
semiquantitative technique. J Bone Miner Res. Sep;8(9):1137-48. 331 
20. Stagi S, Manoni C, Scalini P, Chiarelli F, Verrotti A, Cecchi C, Lapi E, Giglio S, Romano S, 332 
de Martino M (2016) Bone mineral status and metabolism in patients with Williams-Beuren 333 
syndrome. Hormones (Athens). Jul;15(3):404-412. 334 
21. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto 335 
S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for 336 
FGF23. Nature. Dec 7;444(7120):770-4. 337 
22. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, 338 
Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 339 
signaling by klotho. J Biol Chem. Mar 10;281(10):6120-3. 340 
23. Razzaque MS, Lanske B (2007) The emerging role of the fibroblast growth factor-23-klotho 341 
axis in renal regulation of phosphate homeostasis. J Endocrinol. Jul;194(1):1-10. Review. 342 
24. Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-343 
15 
 
Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S (2007) Hyperostosis-344 
hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with 345 
augmented processing of fibroblast growth factor 23. J Bone Miner Res. Feb;22(2):235-42. 346 
25. El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, 347 
Fedarko NS, Collins MT (2016) Stability and degradation of fibroblast growth factor 23 348 
(FGF23): the effect of time and temperature and assay type. Osteoporos Int Jul;27(7):2345-349 
53. 350 
26. Smith ER, McMahon LP, Holt SG (2013) Method-specific differences in plasma fibroblast 351 
growth factor 23 measurement using four commercial ELISAs. Clin Chem Lab Med 352 
Oct;51(10):1971-81. 353 
27. Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact 354 
and C-terminal FGF23 measurements. J Clin Endocrinol Metab. Sep;97(9):3357-65. 355 
28. Pool LR, Wolf M (2017) FGF23 and Nutritional Metabolism, Ann Rev Nutr; 37:247–68 356 
29. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, et 357 
al. (2012). Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 358 
23:1190–97 359 
30. Eller-Vainicher C, Cairoli E, Zhukouskaya VV, Morelli V, Palmieri S, Scillitani A, Beck-360 
Peccoz P, Chiodini I. Prevalence of subclinical contributors to low bone mineral density 361 
and/or fragility fracture. Eur J Endocrinol. 2013 Jul 15;169(2):225-37. 362 
31. Albers J, Schulze J, Beil FT, Gebauer M, Baranowsky A, Keller J, Marshall RP, Wintges K, 363 
Friedrich FW, Priemel M, Schilling AF, Rueger JM, Cornils K, Fehse B, Streichert T, 364 
Sauter G, Jakob F, Insogna KL, Pober B, Knobeloch KP, Francke U, Amling M, Schinke T 365 
(2011) Control of bone formation by the serpentine receptorFrizzled-9. J Cell Biol. Mar 366 
21;192(6):1057-72. 367 
32. Tenenhouse HS (1999) X-linked hypophosphataemia: a homologous disorder in humans and 368 
mice. Nephrol Dial Transplant. Feb;14(2):333-41. Review. 369 
16 
 
33. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD (1998). Intrinsic 370 
mineralization defect in Hyp mouse osteoblasts. Am J Physiol. Oct;275(4 Pt 1):E700-8. 371 
34. Bruin WJ, Baylink DJ, Wergedal JE (1975). Acute inhibition of mineralization and 372 
stimulation of bone resorption mediated by hypophosphatemia. Endocrinology. 373 
Feb;96(2):394-9. 374 
35. Baylink D, Wergedal J, Stauffer M (1971) Formation, mineralization, and resorption of 375 
bone in hypophosphatemic rats. J Clin Invest. Dec;50(12):2519-30. 376 
36. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, 377 
Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-378 
hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. Oct;195(1):125-379 
31. 380 
  381 
17 
 
Figure 1: Ionized calcium values in WS patients and controls.  382 
